Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sigma-Aldrich to sell Pfizer compounds to research community

Sigma-Aldrich to sell Pfizer compounds to research community

16th March 2010

Sigma-Aldrich is to sell around 100 small molecule compounds developed by Pfizer in a move which will aid the research community’s studies into biological systems.

Under the terms of the agreement, the compounds are to be sold to life science researchers for the purposes of target characterisation, assay development and in vivo animal model applications, with many molecules being made available for the first time.

This selection will initially include compounds such as atorvastatin, sildenafil and celecoxib, with Sigma-Aldrich planning to add further compounds on a regular basis.

Dr David Smoller, president of Sigma Life Science’s biotech research business unit, said this would allow the science community to access “interesting and research-relevant bioactive small molecules”.

He added: “This multi-compound deal not only enriches our extensive portfolio of products ? but provides valuable resources that will enable our customers to modulate their protein targets.”

Last week, the science firm licensed a new organic polymer technology developed by the Australian Commonwealth Scientific and Industrial Research Organization, which is designed to allow better control over polymer weight and structure.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.